Q2 Earnings Estimate for Fate Therapeutics Issued By Wedbush

Fate Therapeutics, Inc. (NASDAQ:FATE) – Analysts at Wedbush boosted their Q2 2025 EPS estimates for Fate Therapeutics in a note issued to investors on Tuesday, May 13th. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will post earnings per share of ($0.36) for the quarter, up from their previous forecast of ($0.43). Wedbush currently has a “Neutral” rating and a $5.00 target price on the stock. The consensus estimate for Fate Therapeutics’ current full-year earnings is ($1.63) per share. Wedbush also issued estimates for Fate Therapeutics’ Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.34) EPS, FY2026 earnings at ($1.09) EPS, FY2027 earnings at ($1.02) EPS, FY2028 earnings at ($1.52) EPS and FY2029 earnings at ($1.60) EPS.

A number of other research firms also recently weighed in on FATE. StockNews.com raised Fate Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday. Stifel Nicolaus decreased their price objective on Fate Therapeutics from $5.00 to $3.00 and set a “hold” rating on the stock in a report on Thursday, March 6th. Needham & Company LLC restated a “hold” rating on shares of Fate Therapeutics in a research note on Wednesday. Robert W. Baird cut their price objective on Fate Therapeutics from $5.00 to $4.00 and set a “neutral” rating for the company in a research report on Wednesday. Finally, Barclays lowered their target price on Fate Therapeutics from $10.00 to $2.00 and set an “overweight” rating for the company in a research note on Wednesday. Eight investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $4.14.

Fate Therapeutics Stock Performance

NASDAQ:FATE opened at $1.01 on Friday. The firm’s 50-day moving average is $1.01 and its 200-day moving average is $1.52. The company has a market cap of $115.75 million, a price-to-earnings ratio of -0.61 and a beta of 2.32. Fate Therapeutics has a 52-week low of $0.66 and a 52-week high of $5.92.

Fate Therapeutics (NASDAQ:FATE) last announced its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.07. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%. The business had revenue of $1.63 million for the quarter, compared to analyst estimates of $1.18 million.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in FATE. Baker BROS. Advisors LP boosted its position in shares of Fate Therapeutics by 8.7% during the fourth quarter. Baker BROS. Advisors LP now owns 3,258,402 shares of the biopharmaceutical company’s stock worth $5,376,000 after purchasing an additional 260,630 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Fate Therapeutics by 10.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,898,377 shares of the biopharmaceutical company’s stock valued at $4,782,000 after buying an additional 279,360 shares in the last quarter. Vestal Point Capital LP lifted its stake in Fate Therapeutics by 2.1% in the first quarter. Vestal Point Capital LP now owns 2,515,850 shares of the biopharmaceutical company’s stock valued at $1,988,000 after buying an additional 50,850 shares in the last quarter. Tang Capital Management LLC boosted its holdings in shares of Fate Therapeutics by 165.1% in the fourth quarter. Tang Capital Management LLC now owns 1,855,954 shares of the biopharmaceutical company’s stock valued at $3,062,000 after buying an additional 1,155,954 shares during the period. Finally, JPMorgan Chase & Co. increased its position in shares of Fate Therapeutics by 18.2% during the third quarter. JPMorgan Chase & Co. now owns 1,837,304 shares of the biopharmaceutical company’s stock worth $6,431,000 after acquiring an additional 283,080 shares in the last quarter. Institutional investors and hedge funds own 97.54% of the company’s stock.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.